Importantly, IGF2 inhibition impeded the formation of an immunosuppressive TME and enhanced the recruitment of antitumor CD8 + cytotoxic T-lymphocytes (CTLs), resulting in markedly improved survival of mice bearing GBM and BCBM tumor. This evidence concerns the gene IGF2 and glioblastoma.